^
Association details:
| Biomarker: | ALK rearrangement + CDKN2B deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | ALK inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Impact of concurrent genomic alterations on clinical outcomes in patients with ALK-rearranged non-small cell lung cancer
Published date:
08/10/2023
Excerpt:
...this study cohort analyzed Next-Generation Sequencing data of 116 patients with metastatic ALK-rearranged NSCLC from five Latin-American cancer centers....All patients (n=116) received a second-generation ALK-TKI...Compared with patients without co-alterations, patients with concurrent CDKN2A/B loss (n=21) had a shorter median PFS [10.2 vs. 34.2 months; p<0.001] and OS [26.2 vs. 80.7 months; p<0.001].
DOI:
https://doi.org/10.1016/j.jtho.2023.08.007
Source:
Title:
Co-occurring Loss of CDKN2A/2B Associated with Worse Survival and Increase Risk of Brain Metastasis in ALK-Rearranged Non-small Cell Lung Cancer
Published date:
08/08/2023
Excerpt:
This study analyzed whether co-occurring alterations impact survival outcomes of metastatic ALK-rearranged NSCLC who received second-generation ALK-TKIs….In patients with a concurrent CDKN2A/B loss (n=21), the median PFS was significantly shorter than those without the co-alteration [10.2 vs. 34.2 months; p<0.001]. As well, the median OS was shorter in patients with a concurrent CDKN2A/B loss, [26.2 vs. 80.7 months; p<0.001].
